Abstract: The present invention relates to a method for increasing the productivity of 2?-fucosyllactose through various changes in culture medium composition and culturing on the basis of lactose, which is a substrate, wherein 2-fucosyllactose can be continuously produced in a high-yield at an optimum lactose concentration discovered by a culturing method of the present invention.

Abstract: Disclosed are a food composition containing 2?-fucosyllactose and a pharmaceutical composition containing 2?-fucosyllactose that are effective in ameliorating, preventing or treating various cerebro-cardiovascular diseases caused by thrombogenesis, and a method for ameliorating a cerebro-cardiovascular disease caused by a thrombus by administering a composition including 2?-fucosyllactose (2?-FL) to a subject in need thereof. The 2?-fucosyllactose (2?-FL) exhibits antagonistic (inhibitory) activity against CRP and collagen, which are agonists of platelets, and thus can be used to inhibit thrombogenesis due to abnormal platelet activity.

Abstract: Disclosed is a method for improving the productivity of 2?-fucosyllactose (2?-FL) through enzymatic treatment. Lactose used as a substrate in the stationary phase during culture is degraded by treatment with a small amount of enzyme, the resulting glucose is consumed to produce guanosine diphosphate-L-fucose as a precursor of 2?-fucosyllactose, and the use of lactose left after culture can be maximally utilized for the production of 2?-fucosyllactose. As a result, it is possible to increase the productivity of 2?-fucosyllactose in an economically efficient manner because additional glucose is not required while minimizing by-products.

Abstract: Disclosed is a method for improving the productivity of 2?-fucosyllactose (2?-FL) through enzymatic treatment. Lactose used as a substrate in the stationary phase during culture is degraded by treatment with a small amount of enzyme, the resulting glucose is consumed to produce guanosine diphosphate-L-fucose as a precursor of 2?-fucosyllactose, and the use of lactose left after culture can be maximally utilized for the production of 2?-fucosyllactose. As a result, it is possible to increase the productivity of 2?-fucosyllactose in an economically efficient manner because additional glucose is not required while minimizing by-products.

Abstract: Disclosed is a method for preventing or treating muscular atrophy or sarcopenia, the method comprising administering a composition comprising 2?-fucosyllactose (2?-FL) as an active ingredient to a subject in need thereof. The composition administered to the subject increases the expression of genes related to mitochondrial function enhancement and mitochondrial biosynthesis, and reduces the expression of atrogin-1 and MuRF1 genes, which are markers for muscular atrophy, thereby providing effects of strengthening muscles and preventing muscular atrophy or sarcopenia.

Abstract: Disclosed are a food composition containing 2?-fucosyllactose and a pharmaceutical composition containing 2?-fucosyllactose that are effective in ameliorating, preventing or treating various cerebrovascular diseases caused by thrombogenesis, and a method for ameliorating a cerebrovascular disease caused by a thrombus by administering a composition including 2?-fucosyllactose (2?-FL) to a subject in need thereof. The 2?-fucosyllactose (2?-FL) exhibits antagonistic (inhibitory) activity against CRP and collagen, which are agonists of platelets, and thus can be used to inhibit thrombogenesis due to abnormal platelet activity.

Abstract: Disclosed is fucosyllactose having antiviral activity and inhibitory activity against viral infection, and a method for preventing or treating a viral infection by administering a composition including fucosyllactose as an active ingredient to a subject in need thereof. It was found that 2?-fucosyllactose and 3-fucosyllactose, which are human milk oligosaccharides (HMOs), have antiviral activity, and in particular, 3-fucosyllactose in vitro and in vivo exhibits much higher antiviral activity and inhibitory activity against viral infection compared to 2?-fucosyllactose and is thus useful as an antiviral agent.

Abstract: Disclosed is a method for producing 3-fucosyllactose using a wild Corynebacterium glutamicum strain. In addition, using the Corynebacterium glutamicum strain, which is a GRAS strain, 3-fucosyllactose can be produced at a high concentration, high yield and high productivity.

Abstract: Disclosed is a method for producing 2?-fucosyllactose from a recombinant Corynebacterium sp. introduced with fucosyltransferase derived from Pseudopedobacter saltans. The recombinant Corynebacterium sp. microorganism introduced with fucosyltransferase derived from Pseudopedobacter saltans is capable of producing 2?-fucosyllactose at a high concentration, high yield and high productivity.

Abstract: Disclosed is a food or pharmaceutical composition containing 2?-fucosyllactose (2?-FL) for preventing a stroke. The food or pharmaceutical composition containing 2?-fucosyllactose (2?-FL) is highly effective in preventing a stroke.

Abstract: Disclosed is a method for producing 2?-fucosyllactose from a recombinant Corynebacterium sp. introduced with fucosyltransferase derived from Pseudopedobacter saltans. The recombinant Corynebacterium sp. microorganism introduced with fucosyltransferase derived from Pseudopedobacter saltans is capable of producing 2?-fucosyllactose at a high concentration, high yield and high productivity.

Abstract: Provided is a method of producing 2?-fucosyllactose including culturing in a medium supplemented with lactose a recombinant Corynebacterium glutamicum transformed to express ?-1,2-fucosyltransferase, transformed to express GDP-D-mannose-4,6-dehydratase, transformed to express GDP-L-fucose synthase, and transformed to express lactose permease, wherein the recombinant Corynebacterium glutamicum has phosphomannomutase and GTP-mannose-1-phosphate guanylyltransferase.